TY  - GEN
AU  - Craddock,Charles F
AU  - Houlton,Aimee E
AU  - Quek,Lynn Swun
AU  - Ferguson,Paul
AU  - Gbandi,Emma
AU  - Roberts,Corran
AU  - Metzner,Marlen
AU  - Garcia-Martin,Natalia
AU  - Kennedy,Alison
AU  - Hamblin,Angela
AU  - Raghavan,Manoj
AU  - Nagra,Sandeep
AU  - Dudley,Louise
AU  - Wheatley,Keith
AU  - McMullin,Mary Frances
AU  - Pillai,Srinivas P
AU  - Kelly,Richard J
AU  - Siddique,Shamyla
AU  - Dennis,Michael
AU  - Cavenagh,Jamie D
AU  - Vyas,Paresh
TI  - Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
SN  - 1557-3265
PY  - 2018///0723
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Azacitidine
KW  - Combined Modality Therapy
KW  - Cyclin-Dependent Kinase Inhibitor p16
KW  - Cyclin-Dependent Kinase Inhibitor p18
KW  - genetics
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Histone Deacetylase Inhibitors
KW  - Humans
KW  - Hydroxamic Acids
KW  - Isocitrate Dehydrogenase
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Treatment Outcome
KW  - Tumor Suppressor Protein p53
KW  - Vorinostat
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1158/1078-0432.CCR-17-1423
ER  -